Our Team at ESTIV: Advancing Human-Relevant Toxicology
The Mattek team is attending the European Society of Toxicology In Vitro (ESTIV) Congress in Maastricht from June 29-July 2 to connect with researchers, regulators, and industry leaders advancing the future of NAMs and human-relevant science. Visit the in vitro experts at Booth 20 to learn how Mattek’s portfolio of assay-ready human microtissues help researchers generate more predictive, physiologically relevant data while reducing reliance on animal testing.
Meet with an Expert On-Site:
Miroslav Kandar, Sales Account Manager
Connect with Miro
Scientific Poster Presentations
EpiVaginal™ in Europe: Cross-Site Reproducibility and Discriminatory Performance Using ET-50 and Multi-Endpoint Readouts
Request a CopyIn addition to being an assay-ready and more human-relevant alternative to the Rabbit Vaginal Irritation Test, Mattek’s EpiVaginal™ is the only commercially available in vitro model of human vaginal tissue that has been referenced in FDA guidance for vaginal irritation assessment. To further expand researchers’ access to EpiVaginal™, Mattek conducted an extensive validation effort to successfully implement and standardize production at its location in Europe.
By incorporating ET-50 measurements and multiple biological endpoints, this study demonstrates strong cross-site reproducibility and predictive performance across multiple laboratories in Europe and the Unites States, highlighting EpiVaginal’s robust reproducibility. As regulatory agencies and industry continue seeking better performing alternatives to animal testing, EpiVaginal™ represents a promising human-relevant approach for evaluating vaginal irritation potential. The model offers the opportunity to generate clinically relevant data while supporting global efforts to replace traditional rabbit-based irritation studies.
Request a copy of the poster or get in touch with our team of experts to learn how EpiVaginal™ supports product safety assessments for pharmaceuticals, medical devices, personal care products, and other applications evaluating vaginal mucosal safety.
This study explores the use of EpiDermFT™, Mattek’s full-thickness human skin model, in an innovative in vitro wound healing application. Containing both epidermal keratinocytes and dermal fibroblasts, EpiDermFT™ mirrors the morphology and biological function of in vivo human skin and provides a more comprehensive platform for studying tissue repair processes, screening therapeutic candidates, and investigating factors that influence wound closure.
Using EpiDermFT™, Mattek researchers have developed an in vitro wound healing model that enables quantitative assessment of cutaneous re-epithelialization. Controlled wounds were created in the epidermal layer using a biopsy punch, and the progression of wound closure monitored directly within the tissue over time, allowing researchers to visualize and measure healing progress in situ. This work demonstrates the expanding applications of advanced microtissue models beyond toxicology into dermatology and translational research, along with the importance of utilizing human-specific platforms when investigating mechanisms of human biology.
Request a copy of the poster or get in touch with our team of experts to learn how EpiDermFT™ offers a valuable tool for evaluating the efficacy of wound-healing therapies and accelerating the development of new treatment strategies.
Visit Mattek at Booth 20
ESTIV continues to be a leading forum for advancing New Approach Methodologies (NAMs) and promoting the adoption of human-relevant science. We look forward to discussing how Mattek’s portfolio of assay-ready 3D human microtissues can support your research, safety assessment, and product development programs.
We look forward to seeing you at ESTIV!
